Cannabinoids are known to affect cognitive function and to trigger or worsen psychiatric symptoms and disorders. This review aims at providing a comprehensive outline of the existing literature on the acute effects of cannabinoids on these domains. Recent and relevant evidence shows that cannabinoid intake acutely affects several basal cognitive domains such as learning, memory, and attention. As well, clear acute impairing effects on decision-making, sensitivity to reward, and inhibition are consistently reported, whereas evidence on compromised working memory and problem solving is less solid. Cannabinoid consumption leads to euphoria, relaxation, and increased sociability but can also trigger undesirable effects such as psychotic symptoms/disorders, anxiety and panic, dysphoria, and negative affect in both clinical and non-clinical samples. Δ9‐tetrahydrocannabinol (THC) seems the main culprit for these acute impairments, while evidence supporting potential protective effects of cannabidiol (CBD) is mixed but continues to grow. Dose and THC:CBD ratio, frequency and chronicity of use, pre-existing vulnerability, and demographic/psychosocial factors may moderate these effects. High-potency cannabis (“skunk”) and synthetic cannabinoids (“spice”) have stronger adverse effects and are more dangerous. The existing literature is limited by heterogeneity in terms of populations investigated, compounds and doses administered, and route of administration. More research on high-potency and synthetic compounds, less explored domains, and the role of CBD is needed. This review provides crucial insights on the acute effects of cannabinoids on cognition and mental health that may have important clinical, social, and legal implications.


The use of cannabinoids for both recreational and medicinal purposes is unceasingly increasing, raising concerns about their acute and long-term effects on human health 1,2. In particular, both occasional and frequent cannabinoid intake has been associated with altered cognitive performance and the development or worsening of psychiatric symptoms 1. However, there seem to be differences in impairments between acute and chronic use 3. Besides physical symptoms (such as conjunctival hyperaemia, xerostomia, increased appetite, tachycardia, and elevated blood pressure), acute cannabinoid intake can produce substantial neuropsychiatric effects that are seen during and shortly after the peak of active metabolites in the bloodstream 1,4,5. Although natural cannabis contains more than 100 phytocannabinoids, its effects are mainly attributed to Δ9-tetrahydrocannabinol (THC), a high-affinity cannabinoid receptors partial-agonist 6,7. Another important cannabinoid is cannabidiol (CBD), a compound that seems to have the ability to counteract psychotic symptoms and cognitive impairment associated with cannabis use, also possibly having anxiolytic properties 8-11. Thus, the acute effects of cannabis mainly depend on the concentrations of THC and CBD as well as on the THC:CBD ratio 4,12-14. In recent years, high-potency cannabis – known as “skunk” – has increasingly taken over the market 15,16. Skunk typically presents with THC concentrations of 12-18% and virtually no CBD 17. Hence, its use is associated with more adverse effects than a typical marijuana/hashish joint and may be especially harmful to mental health 15. Besides, there is a growing diffusion of synthetic cannabinoids (SCs), which became popular as “legal highs” under brand names such as “Spice” and “K2” 9,18. Hundreds of different types of SCs have been isolated worldwide 9. Notably, these compounds have extra ingredients (preservatives, additives, fatty acids, amides, esters, benzodiazepines, and O-desmethyltramadol) that are added purposely to induce greater psychoactive effect and as masking agents 19-21. SCs generally have more potent effects than THC 6,7,18, with an earlier onset and peak as well as a shorter duration 22. The acute effects produced by cannabinoids also depend on other factors such as the route of administration (with edibles producing delayed but stronger and longer-lasting effects than smoked cannabinoids), the individual susceptibility to single components, and previous use habits with the subsequent development of tolerance 5,12,13,23. Over the decades, a substantial body of evidence documenting the acute psychoactive effects of cannabinoids has accumulated. With the aim of providing a well-rounded understanding of the complex interplay between cannabinoids and brain physiopathology, in this review we will synthesise the literature available on how their intake acutely impacts cognitive function and increases the risk of psychiatric symptoms and disorders.


It is well-established that acute cannabinoid use transiently diminishes the ability of the brain to hold and process information, and evidence that cannabis intoxication is associated with short-term impairment across several cognitive domains is substantial 3,13. Data regarding SCs, albeit suggesting even more severe cognitive impairments, are still sparse 9,24. Notably, cognitive function emerges as the domain displaying the highest degree of tolerance to the acute effects of cannabinoids in frequent users 3,23.

Verbal learning and memory

The disruption of verbal learning and memory is one of the most frequently observed acute effects of cannabinoids 3,13. The encoding of new memories is compromised during cannabinoid intoxication, leading to subsequent deficits in recalling them, while the retrieval of old memories consolidated when not under influence seems unaffected 13,25. Clear data are available regarding the acute impairing effects of THC on immediate and delayed recall and sometimes recognition accuracy 3. In people using cannabis more than once a week, evidence suggests a development of tolerance to the memory-impairing effects of acute THC intake 26. Notably, impaired verbal learning and memory are consistently observed across different age groups (including adolescents and young adults) and even in occasional users.3 Significant associations between poorer performance in regular users and dose, frequency, quantity, duration, early age of onset of cannabis use, THC:CBD ratio, and SC use have been reported, with long-term users experiencing greater impairment 24,27. Improvement or recovery with abstinence has been observed in some studies, but not consistently 3. In contrast, CBD seemingly offers protection against the acute memory-impairing effects of THC 3,13,28.


The compromised ability to focus and sustain attention has long been recognized as a defining feature of cannabinoid intoxication 3,9,12 and documented in several studies in both adolescent and adult users 3. Acute exposure to cannabinoids impairs focused, divided, or sustained attention, often in a dose-dependent manner 12. Furthermore, false alarms are increased under influence of THC 29. Individuals who use cannabinoids daily may develop tolerance, resulting in milder impairments 3, but conversely seem to remain partially impaired when they go abstinent 30.

Executive function

The acute intake of cannabis has notable but differential effects on executive function 31-33. These effects are mainly due to THC, while research on the effects of CBD is scarce 34. Evidence on the acute effects of SCs is preliminary and mostly preclinical 34.

Acute cannabis intake causes impairments in working memory 13,31, though inconsistently 32 and differentially across a wide range of tasks 3. Cannabis-induced deficits in working memory are seen more in the ability to manipulate information while it is “online” (e.g., when doing mental arithmetic) than in the ability to retain it for brief periods (for instance, when remembering a telephone number before dialling it) 13. Performance accuracy after THC intake seems decreased for moderately high working memory loads only but enhanced for low working memory loads, possibly reflecting a compensational neural mechanism 35. Interestingly, impairments have been reported in recent or heavy users – with greater frequency and quantity of use correlated with poorer performance – but not in older users 3. Impaired working memory typically remains after other acute effects have subsided 31 and may persist even for a few weeks, but appears to mostly resolve with longer abstinence 3.

During acute cannabis intoxication, individuals tend to exhibit heightened tendencies towards risky decision-making, impaired inhibition, and increased sensitivity to reward 3, although research findings are somewhat mixed and task-dependent 13. Acute THC administration putatively affects decision-making by altering sensitivity to reward and punishment 3. Acute cannabis use has also been associated with poor inhibitory control, with decreased inhibition efficiency and increased inhibition errors in a dose-dependent manner 3,12,31,32. Interestingly, people who are more susceptible to the psychotogenic effects of cannabis seem more likely to make inhibition errors than those who are not 36. These alterations comprehensively lead to an increase in risk-taking behaviours, a feature observed in both infrequent and regular cannabis users 3,37,38. All these impairments, together with cannabinoid-induced motor function deficits, have implications for activities that demand precise motor coordination and attentional focus, such as driving 3. Notably, these negative effects on cognitive function seem to be offset when cannabis also contains CBD 12,31.

THC administration was found to impair planning, reasoning, association, task performance, and problem solving, though not in all studies 3. Interestingly, these effects look consistent across samples of occasional, moderate, and heavy users but generally tend to be relatively mild, possibly because of compensatory neural mechanisms 3,32. Verbal fluency may also be affected by acute cannabis use, with the existing body of research, albeit narrow, seemingly suggesting that impairments are more likely to occur in older individuals with longer durations of exposure, while in younger users it may depend on factors such as their intellectual capacity and the specific task 3. Finally, although the subjective effect of cannabis distorting time is well known, objective evidence about cannabinoid intoxication and altered time estimation is extremely limited 3. Some lines of evidence have suggested that a psychoactive dose of THC increases internal clock speed, with time overestimation and underproduction 39. This effect seems not to be dose-related and blunted in chronic cannabis smokers 39.


The intoxication effects of cannabis are described by users as mild euphoria and “high”, relaxation, increased sociability, decreased anxiety and boredom, and enhanced sensory-perceptive experiences, all within a general pleasant feeling 9,40,41. Non-clinical populations consistently rank relaxation high as a reason for use 40. Nevertheless, a number of undesired psychiatric symptoms can be triggered by acute cannabis consumption in both occasional and frequent cannabis consumers, whether already affected by a psychiatric disease or without a history of mental illness 9,12,42-44. First-time use, dose, THC concentration and THC:CBD ratio, frequency of use, personality traits, and pre-existing vulnerability are among the main moderating factors 9,12,40. SCs can induce reactions similar to those occurring with natural cannabis, however they occur more frequently, peak early, are more pronounced, and show more variability, ranging from sedation to agitation 22,45,46. In studies comparing natural cannabis and SC users, SCs were correlated with more psychotic symptoms, agitation, and longer hospitalizations 47. Some psychiatric effects may be experienced for days and weeks after consuming SC products 48.

Psychotic symptoms

Cannabinoids can produce acute, transient, dose-dependent psychosis-like effects in people without a history of mental illness, especially at high doses 4,16,43,44,49. Dose-dependent psychotic experiences have been reported by 15-50% of individuals in community surveys 40. Symptoms include depersonalization, derealization, dream-like euphoria, disorientation, delusions, hallucinations, paranoia, and psychomotor agitation 4,50. Some lines of evidence suggest that THC can lead not only to auditory speech hallucinations but also to visual distortions and illusions 4. These symptoms generally resolve in a short time (few hours) but may last up to a week, and are generally followed by full recovery 51. Negative symptoms of psychosis, including decreased affective range, spontaneity, and rapport, as well as psychomotor retardation and emotional withdrawal, were also reported in several studies and determined not to be related to self-rated sedation 52,53.

Heavy cannabinoid use may lead to an acute functional psychosis, similar to an acute schizophreniform disorder and lacking the organic features of a toxic psychosis.4 In some cases, cannabinoid-induced psychotic episodes may persist for a substantial period of time after acute intoxication 54. This happens especially with SCs, giving rise to the term “spiceophrenia” 16,19,40,48. The risk of developing psychotic illness in vulnerable individuals seems to be dose-dependent 16,55. Beginning cannabis use at a younger age may potentially elevate the susceptibility to experiencing psychotic symptoms or developing full psychotic disorders 43, but this issue remains uncertain 42.

In subjects with pre-existing schizophrenia, the acute use of cannabinoids can lead to re-emergence or worsening of symptoms and even require hospitalization in those who were psychiatrically stable and adherent to medications 40,43,44. However, although smoking cannabis seems to worsen negative affect and increase hallucinations in individual with psychosis56, these people describe relief of dysphoria, relaxation, increased socialization, enhancement of positive affect, and, in some cases (10%), amelioration of psychotic symptoms 57-59. This, together with the fact that the increases in hallucinations are delayed, may explain cannabis use despite the worsening of positive symptoms in this population 56.

The psychotogenic effects of cannabis are largely attributable to THC but the mechanisms through which these occur and which factors predict vulnerability are not completely clear 42. Some data provide evidence for a modest increase in striatal dopamine transmission after acute administration of THC, although to a far lesser extent than other recreational drugs 13. Besides dopaminergic transmission, other potential candidate mechanisms of psychosis-like symptoms include excitatory-inhibitory imbalance between GABAergic 60 and glutamatergic 61 systems. The use of SCs may cause even more frequent and more severe psychotic disorders and psychosis-like conditions6, although their role in psychosis seems more complex than any single chemical component might explain, and these effects may not be a simple extension of the typical effects of natural cannabis 62. Those experiencing psychotic episodes related to SC use are also reported to present with higher/more frequent levels of agitation and behavioral dyscontrol compared to those psychotic episodes described in natural cannabis misusers 63. The moderating role of CBD on the development of psychotic symptoms after acute cannabis intake is less clear: CBD may attenuate psychosis-like symptoms induced by THC in non-clinical samples of healthy volunteers, especially when CBD is administered immediately before THC 11. Further, at high doses (800-1000 mg), CBD seems potentially effective in reducing positive – but not negative – symptoms of schizophrenia 8. However, these beneficial effects of CBD are not unequivocal across all available studies 42. Since the interest in understanding the effects of CBD on psychotic manifestations is rapidly increasing8, research is likely to provide further insights in the near future.

Anxiety and panic

Anxiety reactions are the symptoms most frequently associated with acute cannabinoid use 51,64. Cannabinoids can cause acute and short-lasting episodes of anxiety, intense fear, panic, and phobic attacks, especially in those who are not habitual users, at high doses, and/or when SCs are used 9,51. These effects are less evident among frequent users, who seem to develop some level of tolerance 12. Individual predisposition to anxiety disorders, history of previous episodes, and context of use are acknowledged risk factors for developing acute cannabinoid-induced anxiety states 51. The anxiogenic properties of THC have been firmly established and seem to occur especially at higher THC dose and THC:CBD ratio 12,51,64. On the other hand, CBD shows a consistent anxiolytic action and seems to decrease the anxiogenic effect of THC when the THC:CBD ratio in cannabis is low without having an anxiogenic effect at high doses 10,65. In view of this, cannabis containing primarily CBD, albeit deserving further investigations, has been suggested as a suitable option to manage anxiety or stress-related disorders 65.


Euphoria, enhancement of positive affect, and increased openness to others are consistently reported 40,56,66 and are described as some of the main reasons for cannabis use 58, although transient dysphoria may develop instead 49. However, while prolonged use of both natural and synthetic products is a well-known risk factor for the insurgence and/or the worsening of acute recurrencies in bipolar disorder 67-69, little is known regarding how its acute intake can cause/trigger manic symptoms in both healthy individuals and people already suffering from bipolar disorder. No accounts of frank and enduring mania after a single use of natural cannabis are available in the literature, and only one case of a manic episode triggered by a single dose of a SC was reported 70. Anyways, grandiosity is often reported among the typical symptoms of acute psychotic episodes induced by cannabinoids 40. Similarly, while chronic cannabinoid use does not have positive long-term effects on the course and outcome of depression 71, there seems to be no data regarding the possible triggering effect of acute cannabinoid intake on the development of long-lasting depressive symptoms. Anyways, cannabis can acutely bring about transient emotional lability, intense introspection, or sadness 24,51,64.


The body of work published on the acute effects of cannabinoids on cognition and mental health is heterogeneous in several factors. The populations included in these studies are quite variable, especially concerning participants’ history of cannabis use, age, and comorbidities. Studies also differ in terms of compounds administered, THC concentration and THC:CBD ratio, and route of administration. In this regard, despite their now widespread use, data about SCs are still limited. Lastly, while the literature is quite substantial with respect to domains such as memory, attention, psychotic symptoms, and anxiety, further research must necessarily be carried out on others in order to provide more consistent evidence.


The available body of evidence indicates that the intake of cannabinoids – and especially of high-potency or synthetic ones – acutely impairs cognitive function and increases the risk of psychiatric symptoms and disorders. On the other hand, the potential health benefits of CBD suggest that it may have a protective role and might potentially be used to treat different neuropsychiatric symptoms and conditions, although some findings are against this trend and more research is needed.

As high-potency cannabis and ever new SCs become more and more available on the market, interest in the medical use of cannabis grows, and the use of cannabinoids continues to rise as a whole, it becomes increasingly crucial to keep on studying their acute effects and develop evidence-based guidelines for their utilization. Progress in the study of cannabinoids and their psychoactive effects will provide more data relevant to clinical, public health, and legal spheres, ultimately helping optimize the potential benefits and concurrently minimize associated risks.

Conflicts of interest statement

The authors declare no conflicts of interest.



Authors’ contributions

D.C.: conceptualization, methodology, investigation, writing - original draft; F.B.: conceptualization, methodology, writing - review & editing, supervision; C.C.: methodology, writing - review & editing, supervision; G.C.: conceptualization, writing - review & editing, supervision, project administration.

Ethical consideration

This study did not involve human subjects and/or animals.


  1. Connor J, Stjepanović D, Le Foll B. Cannabis use and cannabis use disorder. Nat Rev Dis Primers. 2021;7. doi:https://doi.org/10.1038/s41572-021-00247-4
  2. Compton W, Han B, Jones C. Marijuana use and use disorders in adults in the USA, 2002-14: analysis of annual cross-sectional surveys. Lancet Psychiatry. 2016;3:954-964. doi:https://doi.org/10.1016/S2215-0366(16)30208-5
  3. Broyd S, van Hell H, Beale C. Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiatry. 2016;79:557-567. doi:https://doi.org/10.1016/j.biopsych.2015.12.002
  4. Karila L, Roux P, Rolland B. Acute and long-term effects of cannabis use: a review. Curr Pharm Des. 2014;20:4112-4118. doi:https://doi.org/10.2174/13816128113199990620
  5. Ranganathan M, D’Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl). 2006;188:425-444. doi:https://doi.org/10.1007/s00213-006-0508-y
  6. Van Amsterdam J, Brunt T, van den Brink W. The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol. 2015;29:254-263. doi:https://doi.org/10.1177/0269881114565142
  7. Pertwee R. The Diverse CB1 and CB2 Receptor Pharmacology of Three Plant Cannabinoids: Δ9-Tetrahydrocannabinol, Cannabidiol and Δ9-Tetrahydrocannabivarin. Br J Pharmacol. 2008;153:199-215. doi:https://doi.org/10.1038/2Fsj.bjp.0707442
  8. Bartoli F, Riboldi I, Bachi B. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. J Clin Med. 2021;10. doi:https://doi.org/10.3390/jcm10061303
  9. Cohen K, Weinstein A. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. Front Public Health. 2018;6. doi:https://doi.org/10.3389/fpubh.2018.00162
  10. Iseger T, Bossong M. A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res. 2015;162:153-161. doi:https://doi.org/10.1016/j.schres.2015.01.033
  11. Englund A, Morrison P, Nottage J. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19-27. doi:https://doi.org/10.1177/0269881112460109
  12. Bloomfield M, Hindocha C, Green S, Wall M, Lees R, Petrilli K, Costello H, Ogunbiyi M, Bossong M, Freeman T. The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacol Ther. 2019;195:132-161. doi:https://doi.org/10.1016/j.pharmthera.2018.10.006
  13. Curran H, Freeman T, Mokrysz C, Lewis D, Morgan C, Parsons L. Keep off the grass? Cannabis, cognition and addiction. Nat Rev Neurosci. 2016;17:293-306. doi:https://doi.org/10.1038/nrn.2016.28
  14. Bhattacharyya S, Morrison P, Fusar-Poli P. Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35:764-774. doi:https://doi.org/10.1038/npp.2009.184
  15. Freeman T, Winstock A. Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol Med. 2015;45:3181-3189. doi:https://doi.org/10.1017/S0033291715001178
  16. Di Forti M, Morgan C, Dazzan P. High-potency cannabis and the risk of psychosis. Br J Psychiatry. 2009;195:488-491. doi:https://doi.org/10.1192/bjp.bp.109.064220
  17. Morgan C, Curran H. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192:306-307. doi:https://doi.org/10.1192/bjp.bp.107.046649
  18. Castaneto M, Gorelick D, Desrosiers N. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014;144:12-41. doi:https://doi.org/10.1016/j.drugalcdep.2014.08.005
  19. Fattore L. Synthetic Cannabinoids-Further Evidence Supporting the Relationship Between Cannabinoids and Psychosis. Biol Psychiatry. 2016;79:539-548. doi:https://doi.org/10.1016/j.biopsych.2016.02.001
  20. Zuba D, Byrska B. Prevalence and co-existence of active components of ‘legal highs’. Drug Test Anal. 2013;5:420-429. doi:https://doi.org/10.1002/dta.1365
  21. Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci. 2011;5. doi:https://doi.org/10.3389/fnbeh.2011.00060
  22. Fantegrossi W, Moran J, Radominska-Pandya A. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity?. Life Sci. 2014;97:45-54. doi:https://doi.org/10.1016/j.lfs.2013.09.017
  23. Colizzi M, Bhattacharyya S. Cannabis use and the development of tolerance: a systematic review of human evidence. Neurosci Biobehav Rev. 2018;93:1-25. doi:https://doi.org/10.1016/j.neubiorev.2018.07.014
  24. Spaderna M, Addy P, D’Souza D. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228:525-540. doi:https://doi.org/10.1007/s00213-013-3188-4
  25. Doss M, Weafer J, Gallo D. Δ9-Tetrahydrocannabinol During Encoding Impairs Perceptual Details yet Spares Context Effects on Episodic Memory. Biol Psychiatry Cogn Neurosci Neuroimaging. 2020;5:110-118. doi:https://doi.org/10.1016/j.bpsc.2019.08.007
  26. Hirvonen J, Goodwin R, Li C. Reversible and regionally selective downregulation of brain cannabinoid CB1 receptors in chronic daily cannabis smokers. Mol Psychiatry. 2012;17:642-649. doi:https://doi.org/10.1038/mp.2011.82
  27. Meier M, Caspi A, Ambler A. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA. 2012;109:E2657-E2664. doi:https://doi.org/10.1073/pnas.1206820109
  28. Yücel M, Lorenzetti V, Suo C. Hippocampal harms, protection and recovery following regular cannabis use. Transl Psychiatry. 2016;6. doi:https://doi.org/10.1038/tp.2015.201
  29. Bossong M, Jansma J, van Hell H. Default mode network in the effects of Δ9-Tetrahydrocannabinol (THC) on human executive function. PloS One. 2013;8. doi:https://doi.org/10.1371/journal.pone.0070074
  30. Bosker W, Karschner E, Lee D. Psychomotor function in chronic daily Cannabis smokers during sustained abstinence. PloS One. 2013;8. doi:https://doi.org/10.1371/journal.pone.0053127
  31. Morie K, Potenza M. A Mini-Review of Relationships Between Cannabis Use and Neural Foundations of Reward Processing, Inhibitory Control and Working Memory. Front Psychiatry. 2021;12. doi:https://doi.org/10.3389/fpsyt.2021.657371
  32. Oomen P, van Hell H, Bossong M. The acute effects of cannabis on human executive function. Behav Pharmacol. 2018;29:605-616. doi:https://doi.org/10.1097/FBP.0000000000000426
  33. Crean R, Crane N, Mason B. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med. 2011;5:1-8. doi:https://doi.org/10.1097/ADM.0b013e31820c23fa
  34. Cohen K, Weinstein A. The Effects of Cannabinoids on Executive Functions: Evidence from Cannabis and Synthetic Cannabinoids-A Systematic Review. Brain Sci. 2018;8. doi:https://doi.org/10.3390/brainsci8030040
  35. Bossong M, Jansma J, van Hell H. Effects of δ9-tetrahydrocannabinol on human working memory function. Biol Psychiatry. 2012;71:693-699. doi:https://doi.org/10.1016/j.biopsych.2012.01.008
  36. Atakan Z, Bhattacharyya S, Allen P. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychol Med. 2013;43:1255-1267. doi:https://doi.org/10.1017/S0033291712001924
  37. De Bellis M, Wang L, Bergman S. Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. Drug Alcohol Depend. 2013;133:134-145. doi:https://doi.org/10.1016/j.drugalcdep.2013.05.020
  38. Rogers R, Wakeley J, Robson P. The effects of low doses of delta-9 tetrahydrocannabinol on reinforcement processing in the risky decision-making of young healthy adults. Neuropsychopharmacology. 2007;32:417-428. doi:https://doi.org/10.1038/sj.npp.1301175
  39. Sewell R, Schnakenberg A, Elander J. Acute effects of THC on time perception in frequent and infrequent cannabis users. Psychopharmacology (Berl). 2013;226:401-413. doi:https://doi.org/10.1007/s00213-012-2915-6
  40. Hanna R, Perez J, Ghose S. Cannabis and development of dual diagnoses: A literature review. Am J Drug Alcohol Abuse. 2017;43:442-455. doi:https://doi.org/10.1080/00952990.2016.1213273
  41. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet. 2009;374:1383-1391. doi:https://doi.org/10.1016/S0140-6736(09)61037-0
  42. Mokrysz C, Shaban N, Freeman T. Acute effects of cannabis on speech illusions and psychotic-like symptoms: two studies testing the moderating effects of cannabidiol and adolescence. Psychol Med. 2021;51:2134-2142. doi:https://doi.org/10.1017/S0033291720001038
  43. Murray R, Di Forti M. Cannabis and Psychosis: What Degree of Proof Do We Require?. Biol Psychiatry. 2016;79:514-515. doi:https://doi.org/10.1016/j.biopsych.2016.02.005
  44. Volkow N, Swanson J, Evins A. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review. JAMA Psychiatry. 2016;73:292-297. doi:https://doi.org/10.1001/jamapsychiatry.2015.3278
  45. Mensen V, Vreeker A, Nordgren J. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology (Berl). 2019;236:2677-2685. doi:https://doi.org/10.1007/s00213-019-05238-8
  46. Seely K, Lapoint J, Moran J. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Progr NeuroPsychopharmacol Biol Psychiatry. 2012;39:234-243. doi:https://doi.org/10.1016/j.pnpbp.2012.04.017
  47. Shalit N, Barzilay R, Shoval G. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study. J Clin Psychiatry. 2016;77:e989-e995. doi:https://doi.org/10.4088/JCP.15m09938
  48. Papanti D, Schifano F, Botteon G. “Spiceophrenia”: a systematic overview of “spice”-related psychopathological issues and a case report. Hum Psychopharmacol. 2013;28:379-389. doi:https://doi.org/10.1002/hup.2312
  49. Morrison P, Zois V, McKeown D. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med. 2009;39:1607-1616. doi:https://doi.org/10.1017/S0033291709005522
  50. Johns A. Psychiatric effects of cannabis. Br J Psychiatry. 2001;178:116-122. doi:https://doi.org/10.1192/bjp.178.2.116
  51. Crippa J, Derenusson G, Chagas M. Pharmacological interventions in the treatment of the acute effects of cannabis: a systematic review of literature. Harm Reduct J. 2012;9. doi:https://doi.org/10.1186/1477-7517-9-7
  52. Morrison P, Stone J. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. Hum Psychopharmacol. 2011;26:77-80. doi:https://doi.org/10.1002/hup.1166
  53. D’Souza D, Perry E, MacDougall L. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology. 2004;29:1558-1572. doi:https://doi.org/10.1038/sj.npp.1300496
  54. Wilkinson S, Radhakrishnan R, D’Souza D. Impact of Cannabis Use on the Development of Psychotic Disorders. Curr Addict Rep. 2014;1:115-128. doi:https://doi.org/10.1007/s40429-014-0018-7
  55. Moore T, Zammit S, Lingford-Hughes A. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007;370:319-328. doi:https://doi.org/10.1016/s0140-6736(07)61162-3
  56. Henquet C, van Os J, Kuepper R. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br J Psychiatry. 2010;196:447-453. doi:https://doi.org/10.1192/bjp.bp.109.072249
  57. Mané A, Fernández-Expósito M, Bergé D. Relationship between cannabis and psychosis: Reasons for use and associated clinical variables. Psychiatry Res. 2015;229:70-74. doi:https://doi.org/10.1016/j.psychres.2015.07.070
  58. Dekker N, Linszen D, De Haan L. Reasons for cannabis use and effects of cannabis use as reported by patients with psychotic disorders. Psychopathology. 2009;42:350-360. doi:https://doi.org/10.1159/000236906
  59. Green B, Kavanagh D, Young R. Reasons for cannabis use in men with and without psychosis. Drug Alcohol Rev. 2004;23:445-453. doi:https://doi.org/10.1080/09595230412331324563
  60. Radhakrishnan R, Skosnik P, Cortes-Briones J. GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC. Neuropsychopharmacology. 2015;40:2047-2056. doi:https://doi.org/10.1038/npp.2015.58
  61. Prescot A, Renshaw P, Yurgelun-Todd D. γ-Amino butyric acid and glutamate abnormalities in adolescent chronic marijuana smokers. Drug Alcohol Depend. 2013;129:232-239. doi:https://doi.org/10.1016/j.drugalcdep.2013.02.028
  62. Deng H, Verrico C, Kosten T. Psychosis and synthetic cannabinoids. Psychiatry Res. 2018;268:400-412. doi:https://doi.org/10.1016/j.psychres.2018.08.012
  63. Brakoulias V. Products containing synthetic cannabinoids and psychosis. Aust N Z J Psychiatry. 2012;46:281-282. doi:https://doi.org/10.1177/0004867411433974
  64. Sharpe L, Sinclair J, Kramer A. Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. J Transl Med. 2020;18. doi:https://doi.org/10.1186/s12967-020-02518-2
  65. Black N, Stockings E, Campbell G. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis [published correction appears in Lancet Psychiatry 2020;7:e3]. Lancet Psychiatry. 2019;6:995-1010. doi:https://doi.org/10.1016/S2215-0366(19)30401-8
  66. Verdoux H, Gindre C, Sorbara F. Effects of cannabis and psychosis vulnerability in daily life: an experience sampling test study. Psychol Med. 2003;33:23-32. doi:https://doi.org/10.1017/s0033291702006384
  67. Gibbs M, Winsper C, Marwaha S. Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord. 2015;171:39-47. doi:https://doi.org/10.1016/j.jad.2014.09.016
  68. Ustundag M, Ozhan Ibis E, Yucel A. Synthetic cannabis-induced mania. Case Rep Psychiatry. 2015;2015. doi:https://doi.org/10.1155/2015/310930
  69. Khan M, Akella S. Cannabis-induced bipolar disorder with psychotic features: a case report. Psychiatry (Edgmont). 2009;6:44-48.
  70. Ekici A, Şahin Ş, Elboğa G. Mania Induced by a Single Dose of Synthetic Cannabinoid. Addict Disord Their Treat. 2021;20:146-148. doi:https://doi.org/10.1097/ADT.0000000000000212
  71. Feingold D, Weinstein A. Cannabis and Depression. Adv Exp Med Biol. 2021;1264:67-80. doi:https://doi.org/10.1007/978-3-030-57369-0_5



Daniele Cavalieri - Department of Medicine and Surgery, University of Milano-Bicocca, Italy

Francesco Bartoli - Department of Medicine and Surgery, University of Milano-Bicocca, Italy

Cristina Crocamo - Department of Medicine and Surgery, University of Milano-Bicocca, Italy

Giuseppe Carrà - Department of Medicine and Surgery, University of Milano-Bicocca, Italy; Division of Psychiatry, University College London, London, United Kingdom

How to Cite
Cavalieri, D., Bartoli, F., Crocamo, C., & Carrà, G. (2024). Acute cognitive and psychiatric effects of cannabinoids. Italian Journal of Psychiatry, 10(1). https://doi.org/10.36180/2421-4469-2024-6
  • Abstract viewed - 92 times
  • PDF downloaded - 41 times